| Literature DB >> 23840318 |
Chiara Manfrin1, Moshe Tom, Gianluca De Moro, Marco Gerdol, Corrado Guarnaccia, Alessandro Mosco, Alberto Pallavicini, Piero Giulio Giulianini.
Abstract
The crustacean Hyperglycemic Hormone (cHH) is a neuropeptide present in many decapods. Two different chiral isomers are simultaneously present in Astacid crayfish and their specific biological functions are still poorly understood. The present study is aimed at better understanding the potentially different effect of each of the isomers on the hepatopancreatic gene expression profile in the crayfish Pontastacus leptodactylus, in the context of short term hyperglycemia. Hence, two different chemically synthesized cHH enantiomers, containing either L- or D-Phe(3), were injected to the circulation of intermolt females following removal of their X organ-Sinus gland complex. The effects triggered by the injection of the two alternate isomers were detected after one hour through measurement of circulating glucose levels. Triggered changes of the transcriptome expression profile in the hepatopancreas were analyzed by RNA-seq. A whole transcriptome shotgun sequence assembly provided the assumedly complete transcriptome of P. leptodactylus hepatopancreas, followed by RNA-seq analysis of changes in the expression level of many genes caused by the application of each of the hormone isomers. Circulating glucose levels were much higher in response to the D-isoform than to the L-isoform injection, one hour from injection. Similarly, the RNA-seq analysis confirmed a stronger effect on gene expression following the administration of D-cHH, while just limited alterations were caused by the L-isomer. These findings demonstrated a more prominent short term effect of the D-cHH on the transcription profile and shed light on the effect of the D-isomer on specific functional gene groups. Another contribution of the study is the construction of a de novo assembly of the hepatopancreas transcriptome, consisting of 39,935 contigs, that dramatically increases the molecular information available for this species and for crustaceans in general, providing an efficient tool for studying gene expression patterns in this organ.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23840318 PMCID: PMC3686806 DOI: 10.1371/journal.pone.0065176
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Morphometric characteristics of the experimental females, their hemolymphatic glucose levels before injection and at their sacrifice.
| Experimental group [n = 8 in each group] | Carapace length [mm] |
| Glucose levels [mg/dL] | |
| 0 min. | 60 min | |||
| Native | 39.4±1.2 | 0.0067±0.0048 | 9.14±0.75 | 14.78±1.93 |
| Sham-injected | 39.4±2.4 | 0.0094±0.0086 | 1.94±0.33 | 1.01±0.59 |
| L-cHH-injected | 41.5±2.0 | 0.0081±0.0065 | 2.36±1.10 | 13.84±3.13 |
| D-cHH-injected | 39.9±1.7 | 0.0025±0.0001 | 2.49±0.83 | 11.45±2.32 |
MMI – molt mineralization index.
Figure 1Box plot of the glycemia values obtained in the four groups S – sham injected, N – intact, L – L-cHH-injected, D- D-cHH-injected at the beginning of the experiment and before sacrifice, one hour post-injection.
Trimming statistics and assembly summary of the Reference dataset.
| Trimming statistics | |
| Number of reads before trimming | 296,112,296 |
| Number of reads after trimming | 289,731,590 |
| Paired-end reads after trimming | 283,857,480 |
| Single reads after trimming | 5,874,110 |
| Sequences discarded during trimming | 6,380,706 |
| Average length before trimming | 101.0 |
| Average length after trimming | 97.2 |
N50, 80 and 90 are the quantiles corresponding to the 50, 80 and 90 percentiles, respectively.
Total number of sequencing reads obtained per animal and the number of the reads mapped and the corresponding percentage.
| Sample | Total number of reads | Mapped reads (%) |
| N1 | 23,784,636 | 13,086,802 (55.0%) |
| N2 | 10,985,623 | 5,738,820 (52.2%) |
| N3 | 17,933,507 | 9,093,453 (50.7%) |
| S1 | 8,589,134 | 4,239,139 (49.4%) |
| S2 | 12,303,830 | 5,904,274 (48.0%) |
| S3 | 14,403,132 | 6,722,862 (46.7%) |
| L1 | 10,579,155 | 6,740,537 (63.7%) |
| L2 | 13,929,531 | 7,154,589 (51.4%) |
| L3 | 11,168,774 | 6,111,228 (54.7%) |
| D1 | 6,239,023 | 2,596,219 (41.6%) |
| D2 | 12,781,748 | 4,431,787 (34.7%) |
| D3 | 7,379,961 | 3,173,378 (43.0%) |
N = native group, S = sham-injected, L = L-cHH injected and D = D-cHH injected.
Number of differentially expressed transcripts in each of the experimental groups.
| Group | Number of differentially expressed transcripts | Up regulated | Down regulated |
| S vs N | 214 | 147 | 67 |
| L vs S | 45 | 30 | 15 |
| D vs S | 917 | 60 | 857 |
FDR corrected p-value <0.01, minimum difference in fold change = 2. S = sham-injected, L = L-cHH injected and D = D-cHH injected.
List of the Interpro domains and GO terms differentially regulated by XOSG removal (S) or by D-cHH-injection (D), detected by the Hypergeometric test.
| Group | Trend | Annotation | p-value | Description |
| S vs N | + | IPR006195 | 0.000117 | Aminoacyl-tRNA synthetase, class II |
| S vs N | + | IPR002930 | 0.000979 | Glycine cleavage H-protein |
| S vs N | + | IPR004365 | 0.000979 | Nucleic acid binding, OB-fold, tRNA/helicase-type |
| S vs N | + | IPR020809 | 0.000979 | Enolase, conserved site |
| S vs N | + | IPR020810 | 0.000979 | Enolase, C-terminal |
| S vs N | + | IPR000537 | 0.00288 | UbiA prenyltransferase family |
| S vs N | + | IPR000941 | 0.00288 | Enolase |
| S vs N | + | IPR004364 | 0.00288 | Aminoacyl-tRNA synthetase, class II (D/K/N) |
| S vs N | + | IPR003604 | 0.00288 | Zinc finger, U1-type |
| S vs N | + | IPR018150 | 0.00288 | Aminoacyl-tRNA synthetase, class II (D/K/N)-like |
| S vs N | + | IPR011053 | 0.00288 | Single hybrid motif |
| S vs N | + | IPR001790 | 0.00564 | Ribosomal protein L10/acidic P0 |
| S vs N | + | IPR016027 | 0.00681 | Nucleic acid-binding, OB-fold-like |
| S vs N | + | IPR012340 | 0.00681 | Nucleic acid-binding, OB-fold |
| S vs N | + | IPR012675 | 0.00921 | Beta-grasp domain |
| S vs N | + | GO:0005960 | 0.000979 | Glycine cleavage compleX |
| S vs N | + | GO:0004659 | 0.000979 | Prenyltransferase activity |
| S vs N | + | GO:0030414 | 0.00288 | Peptidase inhibitor activity |
| S vs N | + | GO:0000287 | 0.00847 | Magnesium ion binding |
| S vs N | + | GO:0004634 | 0.00921 | Phosphopyruvate hydratase activity |
| S vs N | + | GO:0004867 | 0.00921 | Serine-type endopeptidase inhibitor activity |
| S vs N | − | IPR001701 | 1.36E-05 | Glycoside hydrolase, family 9 |
| S vs N | − | IPR012341 | 1.89E-05 | Six-hairpin glycosidase |
| S vs N | − | IPR008928 | 1.89E-05 | Six-hairpin glycosidase-like |
| S vs N | − | IPR017853 | 0.000453 | Glycoside hydrolase, superfamily |
| S vs N | − | IPR011583 | 0.0023 | Chitinase II |
| S vs N | − | IPR001223 | 0.0023 | Glycoside hydrolase, family 18, catalytic domain |
| S vs N | − | IPR013781 | 0.00314 | Glycoside hydrolase, catalytic domain |
| S vs N | − | GO:0005975 | 0.000496 | Carbohydrate metabolic process |
| S vs N | − | GO:0043169 | 0.000584 | Cation binding |
| S vs N | − | GO:0003824 | 0.000858 | Catalytic activity |
| S vs N | − | GO:0004568 | 0.0023 | Chitinase activity |
| D vs S | + | IPR013128 | 0.0000548 | Peptidase C1A, papain |
| D vs S | + | IPR013201 | 0.000777 | Proteinase inhibitor I29, cathepsin propeptide |
| D vs S | + | IPR000668 | 0.0024 | Peptidase C1A, papain C-terminal |
| D vs S | + | GO:0008234 | 0.000113 | Cysteine-type peptidase activity |
| D vs S | + | GO:0004197 | 0.00544 | Cysteine-type endopeptidase activity |
| D vs S | − | IPR000941 | 0.0058 | Enolase |
| D vs S | − | IPR011042 | 0.0058 | Six-bladed beta-propeller, TolB-like |
| D vs S | − | GO:0006096 | 0.000818 | Glycolysis |
| D vs S | − | GO:0030234 | 0.00444 | Enzyme regulator activity |
+ designates up-regulation and − down-regulation.
Figure 2Expression trend of transcripts altered by XOSG ablation and restoring their native level following D-cHH injection.
A Up-regulated transcripts following XOSG ablation. B Down-regulated transcripts following XOSG ablation.